

Studies evaluating VTE incidence with GAHT use in transgender women:

^a Relative to age-matched cisgender women

^b Relative to age-matched cisgender men

IRRs calculated according to [BUMC](#) using data from [Silverstein et al.,1998](#)

* Value was estimated/calculated from other available study data

** IRR could not be accurately obtained due to study methodology

BOLD TEXT indicates IRR significant at p=0.05

CPA = Cyproterone Acetate; LHRH = LHRH Agonist; EE = Ethinylestradiol; CEEs = Conjugated Equine Estrogens; E2 = Estradiol; EV = Estradiol Valerate; EU = Estradiol Undecylate

Design and setting	Sample	Follow-up	Regimen	Unadjusted IR	IRR ^a (95% CI)	IRR ^b (95% CI)	Source
Retrospective cohort study, VUMC, The Netherlands	n = 303 (age range: 16 to 67; median age: 32)	~1,670 total patient years*	CPA 100 mg/day p.o. + EE 100 µg/day p.o. (n = 258) or EU 200 to 800 mg/month i.m. (n = 45)	1,140 per 100,000 patient years	15.20 (9.18 to 25.18)	29.23 (16.77 to 51.0)	Asscheman, Gooren & Eklund.,1989
Retrospective cohort study, VUMC, The Netherlands	n = 816 (age range: 18 to 86; mean age: 41)	7,734 total patient years	CPA 100 mg/day p.o. + EE 100 µg/day p.o. (n = 678) or E2 50 to 100 µg/24 hours t.d. (n = 138)	582 per 100,000 patient years*	6.93 (4.69 to 10.24)	7.28 (4.88 to 10.84)	van Kesteren et al.,1997
Prospective cohort study, Erlangen University Hospital, Germany	n = 60 (age range: ?; mean age: 38.4)	120 total patient years	LHRH 3.8 mg/4 weeks s.c. + EV 6 mg/day p.o. (n = 60)	833 per 100,000 patient years*	11.26 (1.56 to 81.27)	18.51 (2.53 to 135.1)	Dittrich et al.,2005
Prospective cohort study, Ghent University Hospital, Belgium	n = 32 (age range: ?; mean age: 41.5)	121.6 total patient years	CPA 100 mg/day p.o. + EV ? mg/day p.o. (n = 32)	0 per 100,000 patient years	N/A	N/A	De Cuyper et al.,2005
Retrospective cohort study, Medical University of Vienna, Austria	n = 162 (age range: ?; mean age: 36.6)	870 total patient years	CPA 50 mg/day p.o. + E2 200 µg/24 hours t.d. (n = 162)	0 per 100,000 patient years	N/A	N/A	Ott et al.,2010
Prospective cohort study, Erlangen University Hospital, Germany	n = 84 (age range: ?; mean age: 36.3)	168 total patient years	LHRH 3.8 mg/4 weeks s.c. + EV 10 mg/10 days i.m. (n = 84)	595 per 100,000 patient years*	8.04 (1.11 to 58.04)	13.22 (1.81 to 96.52)	Mueller et al.,2011
Retrospective case-control study, CHX GIC, United Kingdom	n = 330 (age range: ?; mean age: 38.5)	~3,000 total patient years*	EV ? mg/day p.o. (n = 163) or EE ? mg/day p.o. (n = 133) or CEEs ? mg/day p.o. (n = 36)	133 per 100,000 patient years*	1.80 (0.65 to 4.95)	2.96 (1.05 to 8.32)	Seal et al.,2012
Prospective case-control study, Ghent University Hospital, Belgium	n = 214 (age range: ?; mean age: 43.7)	~1,650 total patient years*	CPA 50 mg/day p.o. + EV 2 mg/day p.o. (n = 91) or E2 50 µg or 1.5mg/24 hours t.d. (n = 105)	667.6 per 100,000 patient years*	7.95 (4.17 to 15.16)	8.35 (4.35 to 15.99)	Wierckx et al.,2013
Prospective cohort study, ENIGI clinics, Belgium, Norway and Italy	n = 53 (age range: ?; mean age: 30.3)	53 total patient years	CPA 50 mg/day p.o. + EV 4 mg/day p.o. (n = 40) or E2 100 µg/day t.d. (n = 13)	0 per 100,000 patient years	N/A	N/A	Wierckx et al.,2014
Retrospective cohort study, Orsola-Malpighi Hospital, Italy	n = 40 (age range: 19 to 55; mean age: 31.2)	40 total patient years	CPA 50 mg/day p.o. (n = 20) or LHRH 3.75 mg/month i.m. (n = 20) + E2 1 to 2 mg/day t.d.	0 per 100,000 patient years	N/A	N/A	Gava et al.,2016
Retrospective cohort study, Whitman-Walker, DC, United States	n = 676 (age range: ?; mean age: 33.2)	1,286 total patient years	E2 4 to 8 mg/day p.o. (n = 676) + CEEs ? mg/day p.o. (n = 42) + P4 ? mg/day p.o. (n = 27)	78 per 100,000 patient years	1.04 (0.14 to 7.48)	2.00 (0.27 to 14.59)	Arnold et al.,2016
Retrospective cohort study, Kaiser, GA and CA, United States	n = 2,842 (age range: ?; mean age: about 35 to 40??)	11,368 total patient years	E2 1 to 10 mg/day p.o. (n = 853) or unknown (likely similar or same) (n = 1,989)	537 per 100,000 patient years	<i>HR: 1.9 (1.4 to 2.7)</i>	<i>HR: 2.0 (1.4 to 2.8)</i>	Getahun et al.,2018
Retrospective cohort study, VUMC, The Netherlands	n = 2,517 (age range: ?; median age: 30)	22,830 total patient years	CPA 50 to 100 mg/day p.o. + EE 100 µg/day p.o. or E2 p.o. or E2 t.d. (? mg/day)	320 per 100,000 patient years*	4.27 (3.08 to 5.90)	8.21 (5.50 to 12.23)	Nota et al.,2019
Retrospective cohort study, Howard Brown Health, IL, United States	n = 2,002 (age range: 20 to 70; median age: 30)	~5,205 total patient years*	E2 ? mg/day p.o. (n = 946) or E2 ? mg/day t.d. (n = 79) E2 ? mg/x weeks i.m. (n = 971)	250 per 100,000 patient years	2.60 (1.42 to 4.76)		Pyra et al.,2020